Fierce Pharma

Two years and five indications later, UCB’s immunology blockbuster Bimzelx [...]

As one long-running feud over the controversial generic drug carve-out [...]

China assets have outgrown a “bargain basement” label as the [...]

Fierce Pharma’s Angus Liu speaks with Harpreet Singh, M.D., chief [...]

In this webinar, which is a rebroadcast from the 2025 PODD [...]

Less than six months after debuting as the first drug [...]

Following an unexpected delay of the CDC vaccine panel’s February [...]

After promising to sell off 7% of its business back [...]

In developing media plans to reach the GLP-1-interested consumer, audio [...]

When BridgeBio presented its quarterly report on Tuesday, it laid [...]